Economic evaluation of an osteoporosis screening campaign using FRAX

In new research presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases today, investigators showed that an osteoporosis screening strategy using FRAX as a pre-screening tool is cost-effective if the follow up of the screening and medication adherence are optimized. FRAX (WHO Fracture Risk Assessment Tool) is a widely used algorithm to determine 10-year risk of fracture based on an individual's risk factors.

Researchers from the University of Maastricht and the University of Liège evaluated the cost-effectiveness of an osteoporosis screening campaign in the Province of Liège (Belgium). A previously validated microsimulation model was used to estimate the incremental cost-effectiveness ratio (ICER), expressed in costs (in €) per quality-adjusted life-year gained (QALY) gained, of the screening/treatment strategy versus no intervention. The screening/treatment strategy consisted of pre-screening using FRAX, followed by a bone densitometry for patients with a positive FRAX result and combined with a 5-year branded alendronate therapy for women diagnosed with osteoporosis ( (BMD) T-score≤−2.5).

The ICER for the screening/treatment strategy versus no intervention in the whole population (mean age=60 years) was estimated at €66,665 and €39,504 per QALY gained assuming real-world and full respectively. ICERs decreased to €55,517 and €28,520 in the population aged over 60 years (mean age= 65 years). The ICER of the screening strategy decreases when improving the follow-up of a positive screening and when increasing fracture risk. Using the price of generic alendronate, the cost-effectiveness improved to €50,880 and €32,293 assuming real-world and full adherence, respectively.

The authors therefore conclude that the osteoporosis screening strategy is cost-effective if the follow up of the screening and are optimized. Therefore, BMD should be performed in all individuals with posi¬tive FRAX score; individuals having a positive BMD diagnosis should be treated and adherence to therapy should be optimized.

Doctor Mickaël Hiligsmann, Assistant Professor in Health Economics and Health Technology Assessment at Maastricht University and Invited Professor at University of Liège, stated, "To further improve the cost-effectiveness of the screening strategy, we suggest targeting screening on women with one or more clinical , or on women aged 65 years and older".

More information: OC 7 Economic evaluation of an osteoporosis screening campaign: using FRAX as a prescreening tool. M. Hiligsmann, W. Ben Sedrine, O. Bruyère, P. Jeholet, V. Misson, G. Pire, J.-Y. Reginster. Osteoporos Int. Vol 25, Suppl. 2, 2014

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Kidney-brain connection may help drive chronic kidney disease

12 hours ago

In addition to affecting blood pressure, high-salt intake can promote kidney function decline in patients with chronic kidney disease. A study appearing in an upcoming issue of the Journal of the American Society of Nephrology (J ...

Flu's grip on U.S. starting to weaken: CDC

13 hours ago

(HealthDay)—After a rough start to the flu season, the number of infections seems to have peaked and is even starting to decline in many parts of the nation, federal health officials reported Thursday.

Litchi fruit suspected in mystery illness in India

13 hours ago

A mysterious and sometimes fatal brain disease that has afflicted children in northeastern India for years could be linked to a toxic substance in litchi fruits, US researchers said Thursday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.